Key result
Targeting the circadian BMAL1-HIF2A-AREG pathway reduces myocardial injury when timed to its circadian phase.
Answers are grounded in this paper and cite their sources.
as a rhythmic target of the BMAL1-HIF2A complex, critical for regulating daytime variations of myocardial injury. Pharmacologically targeting the BMAL1-HIF2A-AREG pathway provides cardioprotection, with maximum efficacy when aligned with the pathway's circadian phase. These findings identify a mechanism governing circadian variations of myocardial injury and highlight the therapeutic potential of clock-based pharmacological interventions for treating ischaemic heart disease.
No takes yet. Share an insight, caveat, or question.
Ruan et al. (2025) studied ischaemic heart disease. Pharmacologically targeting the BMAL1-HIF2A-AREG pathway was evaluated on myocardial injury. Pharmacologically targeting the BMAL1-HIF2A-AREG pathway provides cardioprotection against myocardial injury, with maximum efficacy when aligned with the pathway's circadian phase.
Synapse has enriched 10 related papers. Consider them for comparative context: